期刊文献+

吉非替尼与紫杉醇联合对卵巢癌细胞凋亡影响的观察 被引量:3

Effect of gefitinib combined with paelitaxel on apoptosis of ovarian cancer cell line HO8910
原文传递
导出
摘要 目的:探讨吉非替尼联合紫杉醇诱导人卵巢癌细胞凋亡的影响。方法:吉非替尼单独或联合紫杉醇作用卵巢癌HO8910细胞,以蛋白质印迹法检测EGFR下游信号磷酸化Akt(p-Akt)、磷酸化细胞外信号调节激酶(p-ERK)和细胞核增殖抗原(PCNA),以MTT法检测细胞增殖率,FCM法检测细胞周期分布和凋亡。结果:吉非替尼单用在0.25~4.00μmol/L浓度范围内呈浓度依赖性抑制卵巢癌HO8910细胞增殖,1.0μmol/L浓度单独作用24h则细胞周期主要分布于G1期,p-Akt、p-ERK和PCNA蛋白水平下降,72h时细胞凋亡增加,与对照组比较,差异均有统计学意义,P<0.05。吉非替尼与紫杉醇合用不仅能更显著的抑制细胞增殖,而且凋亡细胞显著增加(P<0.05),与对应浓度单用紫杉醇比较,差异均有统计学意义,P<0.05。结论:吉非替尼与紫杉醇合用能显著抑制卵巢癌HO8910细胞增殖、诱导凋亡,两种药物合用具有协同作用。 OBJECTIVE: To observe the effect of gefitinib combined with paelitaxel on proliferatio of human ovarian cancer cell line HO8910,and to discuss its possible mechanism.METHODS: Ovarian cancer cells were treated with EGFR inhibitor gefitinib alone or in combination with paelitaxel.Western blot analysis was used to assess the activation of the common downstream signals of Akt,ERK,and PCNA(Proliferating Cell Nuclear Antigen).MTT assay was used to determine the cell proliferation rate.FCM for cell cycle phases and apoptosis.RESULTS: From 0.25 to 4.00 μmol/L concentratin,gefitinib alone inhibited proliferation of cells HO8910 at dose-dependence,and the cycle of cells treated gefitinib(1.0 μmol/L) was main G1 phase,and level of p-Akt,p-ERK,and PCNA proteins decreased significantly at 24 h,and cell apoptosis increased at 72 h,compared with control(P0.05).A combination of gefitinib and paelitaxel resulted in significant decreases in cell proliferation in HO8910 cells,and further induced cell apoptosis,compared with paelitaxel alone.CONCLUSIONS: Gefitinib can suppress the EGFR downstream signaling activation,and enhanced responses of ovarian cancer cells to paelitaxel.The combination treatment produced synergistic inhibition.
出处 《中华肿瘤防治杂志》 CAS 北大核心 2012年第2期106-109,共4页 Chinese Journal of Cancer Prevention and Treatment
基金 湖南省卫生厅科研计划课题(B2011-o89)
关键词 卵巢肿瘤/药物疗法 细胞增殖 细胞凋亡 ovarian neoplasms/drug therapy cell proliferation apoptosis
  • 相关文献

参考文献11

  • 1Maihle NJ,Baron AT,Barrette BA,et al.EGF/ErbB receptorfamily in ovarian cancer[J].Cancer Treat Res,2002,107:247-258.
  • 2Lassus H,Sihto H,Leminen A,et al.Gene amplification,mu-tation,and protein expression of EGFR and mutations of ERBB2in serous ovarian carcinoma[J].J Mol Med,2006,84:671-681.
  • 3Stadlmann S,Gueth U,Reiser U,et al.Epithelial growth fac-tor receptor status in primary and recurrent ovarian cancer[J].Mod Pathol,2006,19(3):607-610.
  • 4Chou TC.Preclinical versus clinical drug combination studies[J].Leuk Lymphoma,2008,49(11):2059-2080.
  • 5Moss NM,Liu Y,Johnson JJ,et al.Epidermal growth factorreceptor-mediated membrane type 1matrix metalloproteinase en-docytosis regulates the transition between invasive versus expan-sive growth of ovarian carcinoma cells in three-dimensional colla-gen[J].Mol Cancer Res,2009,7(6):809-820.
  • 6Brustmann H.Epidermal growth factor receptor expression in serousovarian carcinoma:an immunohistochemical study with galectin-3andcyclin D1and outcome[J].Int J Gynecol Pathol,2008,27(3):380-389.
  • 7Cowden Dahl KD,Symowicz J,Ning Y,et al.Matrix metallo-proteinase 9is a mediator of epidermal growth factor-dependente-cadherin loss in ovarian carcinoma cells[J].Cancer Res,2008,68(12):4606-4613.
  • 8Alper O,Bergmann-Leitner ES,Bennett TA,et al.Epidermalgrowth factor receptor signaling and the invasive phenotype of o-varian carcinoma cells[J].J Natl Cancer Inst,2001,93(18):1375-1384.
  • 9Arteaga CL.ErbB-targeted therapeutic approaches in human cancer[J].Exp Cell Res,2003,284(1):122-130.
  • 10陈楠,张红雨,彭培建,孟晓军.顺铂联合吉非替尼对鼻咽癌细胞生长抑制及其机制的探讨[J].中华肿瘤防治杂志,2011,18(8):575-579. 被引量:3

二级参考文献21

  • 1郭建友,霍海如,姜廷良.衡量联合用药作用研究方法评价[J].中药药理与临床,2005,21(3):60-64. 被引量:12
  • 2Liu J P, Baker J, Perkins A S, et al. Mice carrying null mutations of the genes encoding insulin-like growth factor 1 (Igf-1) and type 1 IGFreceptor (Igflr)[J]. Cell, 1993, 75(1): 59-72.
  • 3Sekharam M, Zhao H, Sun M, et al. Insulin-like growth factor 1 receptor enhances invasion and induces resistance to apoptosis of colon cancer cells through the Akt/Bcl-x(L) pathway[J]. Cancer Res, 2003, 63(22): 7708-7716.
  • 4Knowlden J M, Hutcheson I R, Barrow D, et al. Insulin-like growth factor-1 receptor signaling in tamoxifen-resistant breast cancer: a supporting role to the epidermal growth factor receptor [J]. Endocrinology, 2005, 146(11): 4609-4618.
  • 5Hakam A, Yeatman T J, Lu L, et al. Expression of insulin like growth factor-1 receptor in human colorectal cancer[J]. Hum Pathol, 1999, 30(10): 1128- 1133.
  • 6Morgillo F, Kim W Y, Kim E S, et aI. Implication of the insulin-like growth factor-IR pathway in the resistance of non small cell lung cancer cells to treatment with gefitinib[J]. Clin Cancer Res, 2007, 13(9): 2795-2803.
  • 7Cappuzzo F, Toschi L, Tallini G, et al. Insulin like growth fac- tor receptor 1 (IGFR-1) is significantly associated with longer survival in non-small-cell lung cancer patients treated with gefitinib[J]. AnnOneol, 2006, 17(7): 1120-1127.
  • 8Yip W K, Leong V C, Abdullah M A, et al. Overexpression of phospho-Akt correlates with phosphorylation of EGF receptor, FKHR and BAD in nasopharyngeal carcinoma[J]. Oncol Rep, 2008,19(2):319-328.
  • 9Giaccone G, Herbst R S, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced NSCLC: a phase Ⅲ trial-INTACT 1[J]. J Clin Oncol, 2004,22 (5): 777- 784.
  • 10Helfrich B A, Raben D, Varella-Garcia M,et al. Antitumor activity of the epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor gefitinib (ZD1839, Iressa) in non-small cell lung cancer cell lines correlates with gene copy number and EGFR mutations but not EGFR protein levels[J]. Clin Cancer Res, 2006, 12(23) :7117 7125.

共引文献2

同被引文献49

  • 1柴红,陈泽泉,余永利.甲状腺髓样癌靶向治疗新进展[J].上海交通大学学报(医学版),2011,31(10):1470-1474. 被引量:3
  • 2NORMAN NO N, DE LUCA A, BIANCO C, et al. Epidermal growth factor receptor (EGFR) signaling in cancer [J]. Gene, 2006, 366(1 ):2-16.
  • 3GUI T, SHEN K. The epidermal growth factor receptor as a therapeutic target in epidermal ovarian cance r[J]. Cancer Epidemiol, 2012, 36(5):490-496.
  • 4SCALTRITI M, BASELGA J. The epidermal growth factor receptor pathway: a model for targeted therapvlj}, Clin Cancer Res, 2006, 12(1 ):5268-5272.
  • 5SKIRNISDOTTIR I, SORBE B, SEIDAL T. The growth factors HER-2/neu and EGFR, their relationship, and their effects on the prognosis of early stage epithelial ovarian cancerlj], Int J Gynecol Cancer, 2001,11 (2):119-129.
  • 6OHTA T, OHMICHI M, SHIBUYA T, et al. Gefitinib (ZD1839) increases the efficacy of cisplatin in ovarian cancer cells[J], Cancer Biol Ther, 2012, 13(6):408-416.
  • 7张冠中.培美曲塞与吉非替尼对人结肠癌细胞株作用的研究[D].中国人民解放军军医进修学院2011
  • 8Zhi Xiao,Nianhua Ding,Guiqing Xiao,Shouman Wang,Yuhui Wu,Lili Tang.Reversal of Multidrug Resistance by Gefitinib Via RAF1/ERK Pathway in Pancreatic Cancer Cell Line[J]. Anat Rec . 2012 (12)
  • 9David Adelstein,Cristina Rodriguez,Lisa Rybicki,Denise Ives,Thomas Rice.A phase II trial of gefitinib for recurrent or metastatic cancer of the esophagus or gastroesophageal junction[J]. Investigational New Drugs . 2012 (4)
  • 10Alessandro Antonelli,Poupak Fallahi,Silvia M. Ferrari,Ilaria Ruffilli,Francesca Santini,Michele Minuto,David Galleri,Paolo Miccoli.New Targeted Therapies for Thyroid Cancer[J]. Current Genomics . 2011 (8)

引证文献3

二级引证文献15

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部